Robert H. Lurie Comprehensive Cancer Center of Northwestern UniversityThe Minds Matter Benefit
We are so grateful to the sponsors, supporters, and attendees, of the 2022 Minds Matter benefit. Support of this event is crucial to fueling innovations within the Malnati Brain Tumor Institute to aid in improving care for MBTI patients and brain tumor patients everywhere.
We cannot wait to see you again for Minds Matter 2023 on May 5, 2023, from 6-11 p.m. at the Ritz-Carlton, Chicago.
Registration and further event details can be found here.
For questions and/or to discuss sponsorship opportunities, please reach out to ashleymay@northwestern.edu.
You don't have to wait to make a difference; there are a number of different ways to support the MBTI year round that can be found on our Donate page.
Minds Matter 2022
On May 20, 230 friends and philanthropists celebrated and supported progress being made in brain tumor research and care at the Minds Matter Benefit. The annual event supports the Lou and Jean Malnati Brain Tumor Institute (MBTI) of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital.
The 2022 fundraiser, held at the Museum of Contemporary Art Chicago, raised nearly $415,000 to help MBTI scientists and clinicians develop and deliver better treatments for patients affected by brain and spinal tumors. Nearly 700,000 people living today—and their families—face the challenging realities of a brain or spinal diagnosis.
In the past year, the Northwestern Medicine team has accelerated research on cancer immunology and immunotherapy, which boosts the immune system’s ability to recognize and kill cancer cells. They also identified a drug treatment for an aggressive brain tumor that doesn’t respond to any other therapies and tested a novel neural stem cell therapy for brain metastases.
“Fundraisers, like Minds Matter, help support ideas—the ideas that maybe started in a research lab or in conversations we were having with a patient about a new protocol or treating a disease,” said James P. Chandler, MD, co-director of the MBTI and the Lavin/Fates professor of Neurological Surgery. “Thank you to our generous community of donors who are enabling us to pursue these ideas and make important strides for our patients in Chicago and beyond.”
